Last reviewed · How we verify
NCT03463798: DYSDIA
Assesment of New Devices for the Diagnostic Evaluation of Diaphragmatic Dysfunction
trial testing Sonar in Diaphragmatic Paralysis in 125 participants. Completed in 21 September 2021.
21 September 2021
Quick facts
| Lead sponsor | Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 125 |
| Start date | 11 June 2018 |
| Primary completion | 21 September 2021 |
| Estimated completion | 21 September 2021 |
| Sites | 1 location across France |
Drugs / interventions tested
- Sonar
- Structured light plethysmography (SLP)
Conditions studied
- Diaphragmatic Paralysis — all drugs for Diaphragmatic Paralysis →
- Healthy Volunteers — all drugs for Healthy Volunteers →
Sponsor
Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil
Who can join
18 and older, any sex, with Diaphragmatic Paralysis or Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
this study aim to evaluate wether new, non-invasive and non-contact devices such as Structured Light Plethysmography (SLP) and Sonar would be able to accurately detect and quantify diaphragm dysfunction (mono-or-bilateral) by assessing the asymmetric chest wall motion generated during spontaneous breathing as compared with a classic, standard and invasive technique.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03463798
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Sonar
Trials testing the same drug.
- NCT06815224 — The Role of Perirenal Fat As Predictor in Diabetic Nephropathy · not yet recruiting
Other recruiting trials for Diaphragmatic Paralysis
Currently open trials in the same condition.
- NCT06257589 — A Chart Review to Evaluate the Safety and Efficacy of Phrenic Nerve Reconstruction for the Treatment of Diaphragmatic Pa · active not recruiting
- NCT06243718 — Phrenic Nerve Reconstruction for the Treatment of Diaphragmatic Paralysis: Patient Experiences and Reported Outcomes. · recruiting
Other Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil trials
Trials by the same sponsor.
- NCT04447196 — Prevalence of Rest Dyspnea and Impact of Non Invasive Ventilation on Breathing Sensations in CCHS Patients · unknown
- NCT04815330 — Patient Dyspnea Under Veno-arterial Extracorporeal Circulation · completed
- NCT04815317 — Sensory and Emotional Modulation of Dyspnea Under Artificial Ventilation in the Intensive Care Unit · NA · completed
- NCT04098094 — Outcomes of RV Dysfunction in Acute Exacerbation of Chronic Respiratory Diseases · unknown
- NCT03753386 — Identification of Respiratory Profiles From Nasal Pressure Signals · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03463798 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil
- Last refreshed: 14 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03463798.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing